Intellia Therapeutics(US:NTLA) Zhi Tong Cai Jing·2025-10-27 15:36Core Viewpoint - Intellia Therapeutics experienced a significant drop of over 45%, closing at $13.90, following the suspension of two Phase 3 clinical trials related to its drug nex-z due to safety concerns [1] Company Summary - Intellia Therapeutics has paused patient dosing and screening for two Phase 3 clinical trials targeting patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy [1] - The suspension was prompted by a report of a patient experiencing grade 4 elevation in liver transaminases and increased total bilirubin after treatment, leading to hospitalization and medical intervention [1] - The company is consulting with experts and considering potential risk mitigation strategies while communicating with regulatory agencies to resume trial recruitment as soon as appropriate [1]